In a widely expected move, the Food and Drug Administration has expanded its emergency use authorization for Pfizer (NYSE: PFE) and BioNTech 's (NASDAQ: BNTX) COVID-19 vaccine to include people as young as 12 years old. https://content.govdelivery.com/accounts/USFDA/bulletins/2d8857e
The widened authorization for BNT162b2 was based on the ability of the vaccine to induce the production of COVID-19 antibodies; the levels of antibodies it generated in clinical trial participants ages 12 through 15 were at least as good as the antibody levels in participants in the 16-to-25 age range.
Those antibodies appear to protect patients from being infected by the coronavirus.
For further details see:
Pfizer and BioNTech's COVID-19 Vaccine Authorized by the FDA for Adolescents